| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Otitis Media | 10 | 2017 | 286 | 2.670 |
Why?
|
| Primary Health Care | 21 | 2024 | 4686 | 2.380 |
Why?
|
| Vision Screening | 4 | 2019 | 72 | 2.170 |
Why?
|
| Pediatrics | 14 | 2024 | 3589 | 1.780 |
Why?
|
| Quality Improvement | 12 | 2024 | 3801 | 1.370 |
Why?
|
| Insurance Claim Review | 3 | 2021 | 741 | 1.360 |
Why?
|
| Xylitol | 4 | 2014 | 23 | 1.100 |
Why?
|
| Respiratory Tract Infections | 2 | 2022 | 1010 | 0.940 |
Why?
|
| Sweetening Agents | 4 | 2014 | 290 | 0.900 |
Why?
|
| Nonprescription Drugs | 3 | 2009 | 118 | 0.880 |
Why?
|
| Community-Acquired Infections | 2 | 2024 | 469 | 0.870 |
Why?
|
| Clinical Coding | 1 | 2024 | 181 | 0.840 |
Why?
|
| Child Health Services | 4 | 2021 | 646 | 0.800 |
Why?
|
| Asthma | 5 | 2021 | 6234 | 0.730 |
Why?
|
| Referral and Consultation | 7 | 2019 | 3600 | 0.720 |
Why?
|
| Child | 44 | 2024 | 80153 | 0.690 |
Why?
|
| Vision Disorders | 2 | 2017 | 1088 | 0.690 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2015 | 574 | 0.630 |
Why?
|
| Lyme Disease | 2 | 2022 | 631 | 0.620 |
Why?
|
| Practice Management, Medical | 1 | 2019 | 191 | 0.600 |
Why?
|
| Brain Concussion | 3 | 2023 | 1404 | 0.590 |
Why?
|
| Office Visits | 2 | 2020 | 595 | 0.580 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2021 | 395 | 0.550 |
Why?
|
| Middle Ear Ventilation | 1 | 2017 | 101 | 0.540 |
Why?
|
| Fee-for-Service Plans | 1 | 2020 | 700 | 0.500 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 559 | 0.480 |
Why?
|
| Physicians, Family | 2 | 2007 | 350 | 0.470 |
Why?
|
| Child, Preschool | 25 | 2024 | 42230 | 0.450 |
Why?
|
| Massachusetts | 8 | 2024 | 8830 | 0.450 |
Why?
|
| Psychiatry | 2 | 2023 | 1693 | 0.440 |
Why?
|
| Pharmaceutical Services | 1 | 2015 | 141 | 0.440 |
Why?
|
| Ambulatory Care | 2 | 2015 | 2775 | 0.410 |
Why?
|
| Private Sector | 1 | 2015 | 398 | 0.400 |
Why?
|
| Nasal Decongestants | 2 | 2008 | 29 | 0.400 |
Why?
|
| Pneumonia | 1 | 2024 | 2143 | 0.390 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 3358 | 0.380 |
Why?
|
| Common Cold | 2 | 2008 | 63 | 0.380 |
Why?
|
| Diarrhea | 3 | 2006 | 1318 | 0.370 |
Why?
|
| Health Education | 1 | 2017 | 1052 | 0.360 |
Why?
|
| Certification | 1 | 2014 | 418 | 0.360 |
Why?
|
| Craniocerebral Trauma | 1 | 2015 | 490 | 0.360 |
Why?
|
| Mass Screening | 5 | 2020 | 5428 | 0.360 |
Why?
|
| Guideline Adherence | 3 | 2017 | 2220 | 0.350 |
Why?
|
| Fluorides | 1 | 2011 | 134 | 0.350 |
Why?
|
| Prescriptions | 1 | 2012 | 386 | 0.350 |
Why?
|
| Infant | 22 | 2024 | 36192 | 0.330 |
Why?
|
| Pandemics | 4 | 2022 | 8654 | 0.330 |
Why?
|
| Pseudoephedrine | 1 | 2008 | 3 | 0.330 |
Why?
|
| Disease Management | 2 | 2017 | 2508 | 0.310 |
Why?
|
| Humans | 68 | 2024 | 761504 | 0.310 |
Why?
|
| Health Care Costs | 2 | 2019 | 3242 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2017 | 4016 | 0.300 |
Why?
|
| Parental Notification | 1 | 2007 | 12 | 0.290 |
Why?
|
| Specialization | 1 | 2012 | 778 | 0.280 |
Why?
|
| Bacterial Vaccines | 2 | 2000 | 401 | 0.280 |
Why?
|
| Antibodies, Bacterial | 4 | 2016 | 1469 | 0.270 |
Why?
|
| Scoliosis | 1 | 2013 | 741 | 0.260 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 4420 | 0.260 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 1670 | 0.250 |
Why?
|
| Telemedicine | 2 | 2022 | 3051 | 0.250 |
Why?
|
| Boston | 6 | 2017 | 9326 | 0.250 |
Why?
|
| Adolescent | 21 | 2024 | 88319 | 0.250 |
Why?
|
| Academies and Institutes | 1 | 2007 | 318 | 0.240 |
Why?
|
| Croup | 1 | 2004 | 23 | 0.240 |
Why?
|
| Cough | 1 | 2008 | 594 | 0.230 |
Why?
|
| Health Surveys | 2 | 2011 | 4061 | 0.220 |
Why?
|
| Vaccines, Conjugate | 3 | 2002 | 328 | 0.220 |
Why?
|
| Streptococcus pneumoniae | 2 | 2000 | 730 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 7407 | 0.220 |
Why?
|
| Mental Disorders | 1 | 2023 | 6845 | 0.210 |
Why?
|
| Male | 38 | 2024 | 360804 | 0.210 |
Why?
|
| Electronic Health Records | 2 | 2019 | 4811 | 0.210 |
Why?
|
| Hernia, Umbilical | 1 | 2024 | 102 | 0.210 |
Why?
|
| Health Expenditures | 1 | 2015 | 2366 | 0.210 |
Why?
|
| Lipid A | 1 | 2002 | 70 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.210 |
Why?
|
| Female | 41 | 2024 | 392644 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.210 |
Why?
|
| Vitamins | 1 | 2011 | 1635 | 0.200 |
Why?
|
| Iron | 1 | 2011 | 1793 | 0.200 |
Why?
|
| Prescription Drugs | 1 | 2009 | 631 | 0.200 |
Why?
|
| Infant Behavior | 1 | 2003 | 156 | 0.200 |
Why?
|
| United States | 15 | 2024 | 72334 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2017 | 4792 | 0.190 |
Why?
|
| Program Development | 2 | 2017 | 1297 | 0.190 |
Why?
|
| Administration, Oral | 4 | 2014 | 4021 | 0.190 |
Why?
|
| Program Evaluation | 3 | 2019 | 2495 | 0.180 |
Why?
|
| Constipation | 2 | 2016 | 563 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 2 | 2000 | 1063 | 0.180 |
Why?
|
| Seasons | 2 | 2022 | 1520 | 0.180 |
Why?
|
| Data Collection | 2 | 2007 | 3322 | 0.170 |
Why?
|
| Disease Progression | 2 | 2018 | 13506 | 0.170 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2002 | 578 | 0.170 |
Why?
|
| Optometry | 1 | 2019 | 29 | 0.160 |
Why?
|
| Adolescent Health Services | 1 | 2021 | 218 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 4 | 2012 | 7390 | 0.160 |
Why?
|
| Acute Disease | 5 | 2014 | 7237 | 0.160 |
Why?
|
| Posture | 1 | 2003 | 957 | 0.160 |
Why?
|
| Mental Health Services | 2 | 2021 | 1730 | 0.160 |
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2000 | 366 | 0.150 |
Why?
|
| Psychotherapy, Brief | 1 | 2019 | 118 | 0.150 |
Why?
|
| Infant, Low Birth Weight | 1 | 2003 | 870 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2011 | 3415 | 0.150 |
Why?
|
| House Calls | 1 | 2019 | 161 | 0.150 |
Why?
|
| Behavioral Medicine | 1 | 2017 | 50 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2004 | 1948 | 0.140 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 266 | 0.140 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2002 | 974 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 1036 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2024 | 80636 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2024 | 2707 | 0.140 |
Why?
|
| Whooping Cough | 1 | 1996 | 86 | 0.130 |
Why?
|
| Suicide, Assisted | 1 | 1996 | 68 | 0.130 |
Why?
|
| Physicians | 2 | 2013 | 4591 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2017 | 563 | 0.130 |
Why?
|
| Child Welfare | 1 | 2019 | 521 | 0.130 |
Why?
|
| Child Behavior | 1 | 2021 | 847 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2004 | 2161 | 0.120 |
Why?
|
| Apnea | 1 | 1996 | 195 | 0.120 |
Why?
|
| Child Psychiatry | 1 | 2017 | 228 | 0.120 |
Why?
|
| Education, Medical, Continuing | 2 | 2019 | 823 | 0.120 |
Why?
|
| Anthropometry | 1 | 2019 | 1349 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2000 | 3810 | 0.120 |
Why?
|
| Tetanus Antitoxin | 1 | 1993 | 8 | 0.120 |
Why?
|
| Phagocytosis | 1 | 2000 | 1528 | 0.110 |
Why?
|
| Tetanus | 1 | 1993 | 51 | 0.110 |
Why?
|
| Age Factors | 4 | 2024 | 18395 | 0.110 |
Why?
|
| Injury Severity Score | 1 | 2017 | 1045 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 1112 | 0.110 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 329 | 0.110 |
Why?
|
| Age Distribution | 2 | 2011 | 2880 | 0.110 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2016 | 262 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2011 | 2048 | 0.110 |
Why?
|
| Otitis Media, Suppurative | 1 | 2013 | 27 | 0.110 |
Why?
|
| Cost Savings | 1 | 2019 | 913 | 0.110 |
Why?
|
| Behavior Therapy | 1 | 2019 | 879 | 0.110 |
Why?
|
| Tetanus Toxoid | 1 | 1993 | 189 | 0.110 |
Why?
|
| Problem-Based Learning | 1 | 2017 | 356 | 0.110 |
Why?
|
| Face | 1 | 2019 | 1026 | 0.110 |
Why?
|
| Prevalence | 4 | 2013 | 15732 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 3205 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1705 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 942 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 981 | 0.110 |
Why?
|
| Probability | 2 | 2008 | 2477 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 1421 | 0.110 |
Why?
|
| Athletic Injuries | 1 | 2023 | 1216 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 1190 | 0.100 |
Why?
|
| Home Care Services | 1 | 2019 | 648 | 0.100 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 365 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2018 | 23995 | 0.100 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 26125 | 0.100 |
Why?
|
| Ophthalmology | 1 | 2019 | 550 | 0.100 |
Why?
|
| Health Care Surveys | 2 | 2017 | 2426 | 0.100 |
Why?
|
| Confidence Intervals | 2 | 2008 | 2927 | 0.100 |
Why?
|
| Otitis Media with Effusion | 1 | 2013 | 115 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2002 | 4544 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2021 | 41487 | 0.100 |
Why?
|
| Skin Tests | 1 | 1993 | 637 | 0.100 |
Why?
|
| Risk Factors | 7 | 2021 | 74206 | 0.100 |
Why?
|
| Hospitals, Pediatric | 2 | 2017 | 1860 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2007 | 3429 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2850 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2014 | 1572 | 0.090 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 7879 | 0.080 |
Why?
|
| Physician's Role | 1 | 1996 | 917 | 0.080 |
Why?
|
| Equipment Design | 1 | 2017 | 3510 | 0.080 |
Why?
|
| Bacterial Proteins | 1 | 2002 | 3847 | 0.080 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5440 | 0.080 |
Why?
|
| Expectorants | 1 | 2008 | 22 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2021 | 3537 | 0.080 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2000 | 168 | 0.080 |
Why?
|
| Mental Health | 1 | 2022 | 3250 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2013 | 803 | 0.070 |
Why?
|
| Canada | 1 | 2013 | 2122 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 3889 | 0.070 |
Why?
|
| Flatulence | 1 | 2006 | 19 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2019 | 8631 | 0.070 |
Why?
|
| Sleep | 1 | 2003 | 4768 | 0.070 |
Why?
|
| Medicaid | 1 | 2020 | 2818 | 0.070 |
Why?
|
| RNA Virus Infections | 1 | 2006 | 19 | 0.070 |
Why?
|
| Giardiasis | 1 | 2006 | 28 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2016 | 2672 | 0.070 |
Why?
|
| Cryptosporidium parvum | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mamastrovirus | 1 | 2006 | 3 | 0.070 |
Why?
|
| Sapovirus | 1 | 2006 | 4 | 0.070 |
Why?
|
| Cryptosporidiosis | 1 | 2006 | 52 | 0.070 |
Why?
|
| Clostridium perfringens | 1 | 2006 | 29 | 0.070 |
Why?
|
| Young Adult | 4 | 2017 | 59243 | 0.070 |
Why?
|
| Norovirus | 1 | 2006 | 37 | 0.060 |
Why?
|
| Self Report | 1 | 2017 | 3724 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5336 | 0.060 |
Why?
|
| Overweight | 1 | 2016 | 2417 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 4853 | 0.060 |
Why?
|
| Rotavirus | 1 | 2006 | 109 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 238 | 0.060 |
Why?
|
| Chickenpox | 1 | 2004 | 96 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2006 | 255 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 1213 | 0.060 |
Why?
|
| Sex Factors | 1 | 2017 | 10552 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2006 | 343 | 0.060 |
Why?
|
| Remission, Spontaneous | 1 | 2024 | 384 | 0.050 |
Why?
|
| Child Day Care Centers | 1 | 2004 | 122 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2009 | 1188 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2008 | 2281 | 0.050 |
Why?
|
| Cholesterol | 1 | 2012 | 2904 | 0.050 |
Why?
|
| Aluminum Compounds | 1 | 2002 | 55 | 0.050 |
Why?
|
| Prospective Studies | 5 | 2019 | 54425 | 0.050 |
Why?
|
| Supine Position | 1 | 2003 | 205 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2017 | 9318 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8224 | 0.050 |
Why?
|
| Prone Position | 1 | 2003 | 196 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1993 | 2151 | 0.050 |
Why?
|
| Infant Care | 1 | 2003 | 180 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2007 | 2645 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3688 | 0.050 |
Why?
|
| Family Health | 1 | 2006 | 1257 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2024 | 26198 | 0.050 |
Why?
|
| Developing Countries | 1 | 2013 | 2885 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2002 | 616 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1664 | 0.040 |
Why?
|
| Feces | 1 | 2006 | 1497 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 856 | 0.040 |
Why?
|
| HN Protein | 1 | 1998 | 8 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6310 | 0.040 |
Why?
|
| Phosphates | 1 | 2002 | 770 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7827 | 0.040 |
Why?
|
| Incidence | 2 | 2006 | 21353 | 0.040 |
Why?
|
| Wedge Argument | 1 | 1996 | 6 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2002 | 1155 | 0.030 |
Why?
|
| Double Effect Principle | 1 | 1996 | 14 | 0.030 |
Why?
|
| Euthanasia, Active | 1 | 1996 | 16 | 0.030 |
Why?
|
| Craniofacial Abnormalities | 1 | 2019 | 319 | 0.030 |
Why?
|
| Catholicism | 1 | 1996 | 33 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2002 | 1560 | 0.030 |
Why?
|
| Games, Experimental | 1 | 2016 | 32 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 14605 | 0.030 |
Why?
|
| Ethics | 1 | 1996 | 94 | 0.030 |
Why?
|
| Euthanasia, Passive | 1 | 1996 | 64 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2093 | 0.030 |
Why?
|
| Jurisprudence | 1 | 1996 | 109 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2000 | 397 | 0.030 |
Why?
|
| Biometry | 1 | 2019 | 563 | 0.030 |
Why?
|
| Euthanasia | 1 | 1996 | 58 | 0.030 |
Why?
|
| Trachea | 2 | 2000 | 1089 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 2319 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2004 | 1359 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2006 | 2598 | 0.030 |
Why?
|
| Immunization | 1 | 2000 | 1228 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 20098 | 0.030 |
Why?
|
| Headache | 1 | 2023 | 1256 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 39106 | 0.030 |
Why?
|
| Birth Weight | 1 | 2003 | 2103 | 0.030 |
Why?
|
| Borrelia burgdorferi | 1 | 2016 | 183 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2002 | 1802 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 10766 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 2019 | 804 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1186 | 0.030 |
Why?
|
| Homicide | 1 | 1996 | 294 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2006 | 4217 | 0.030 |
Why?
|
| Intention | 1 | 1996 | 347 | 0.030 |
Why?
|
| Telephone | 1 | 2016 | 627 | 0.030 |
Why?
|
| Adult | 5 | 2019 | 221177 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 1993 | 397 | 0.030 |
Why?
|
| Mothers | 1 | 2003 | 2198 | 0.030 |
Why?
|
| Reference Values | 1 | 2019 | 4920 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14666 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 1996 | 617 | 0.020 |
Why?
|
| Patient Preference | 1 | 2019 | 924 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5486 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1998 | 1804 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1624 | 0.020 |
Why?
|
| Attitude | 1 | 1996 | 775 | 0.020 |
Why?
|
| Counseling | 1 | 2019 | 1547 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1996 | 783 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2000 | 1886 | 0.020 |
Why?
|
| Respiration, Artificial | 2 | 2000 | 2628 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2012 | 322 | 0.020 |
Why?
|
| Peru | 1 | 1993 | 891 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 10209 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2016 | 1038 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2019 | 1647 | 0.020 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2010 | 33 | 0.020 |
Why?
|
| Amoxicillin | 1 | 2010 | 180 | 0.020 |
Why?
|
| Gastroenterology | 1 | 2015 | 577 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2019 | 5247 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 1996 | 1089 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 169289 | 0.020 |
Why?
|
| Cytokines | 1 | 2002 | 7396 | 0.020 |
Why?
|
| Health Promotion | 1 | 2019 | 2214 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1996 | 2107 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3461 | 0.020 |
Why?
|
| Motivation | 1 | 1996 | 2006 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 15500 | 0.020 |
Why?
|
| Middle Aged | 2 | 2014 | 220895 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2016 | 2180 | 0.020 |
Why?
|
| Prenatal Care | 1 | 1993 | 1139 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 4063 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2016 | 64680 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2012 | 1186 | 0.010 |
Why?
|
| Terminal Care | 1 | 1996 | 1760 | 0.010 |
Why?
|
| Linear Models | 1 | 1993 | 5871 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1998 | 9177 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 1996 | 4330 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9610 | 0.010 |
Why?
|
| Algorithms | 1 | 2019 | 14031 | 0.010 |
Why?
|
| Viral Fusion Proteins | 1 | 1998 | 100 | 0.010 |
Why?
|
| Intubation | 1 | 1998 | 139 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3245 | 0.010 |
Why?
|
| Nasal Mucosa | 1 | 2000 | 416 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13255 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 640 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 168459 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 2219 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2000 | 1329 | 0.010 |
Why?
|
| Pregnancy | 1 | 1993 | 29874 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2000 | 12341 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2000 | 15842 | 0.000 |
Why?
|